Alyeska Investment Group
NAMS icon

Alyeska Investment Group’s NewAmsterdam Pharma NAMS Stock Holding History

Alyeska Investment Group’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-114,707
Closed -$2.95M – 614
2024
Q4 		$2.95M Sell
114,707
-193,451
-63% -$4.11M 0.01% 445
2024
Q3 		$5.12M Buy
308,158
+222,517
+260% +$3.85M 0.03% 354
2024
Q2 		$1.65M Buy
85,641
+50,000
+140% +$1M 0.01% 428
2024
Q1 		$843K Buy
+35,641
New +$723K 0.01% 420
2023
Q4 		– Sell
-44,432
Closed -$407K – 616
2023
Q3 		$411K Sell
44,432
-85,115
-66% -$922K ﹤0.01% 456
2023
Q2 		$1.54M Buy
+129,547
New +$1.72M 0.01% 424
2023
Q1 		– Sell
-200,000
Closed -$2.52M – 514
2022
Q4 		$1.89M Buy
+200,000
New +$1.99M 0.02% 322

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Alyeska Investment Group's NAMS Position: Q1 2025 in Review

Alyeska Investment Group sold out of NewAmsterdam Pharma (NAMS) in Q1 2025, closing a stake of 114,707 shares — an estimated $2.95M sold.

Alyeska Investment Group first reported a position in NAMS in Q4 2022 and held it in 7 quarters. The position peaked at $5.12M in Q3 2024. 126 funds tracked by Wall St. Rank hold NAMS as of Q1 2025.

  • Alyeska Investment Group reported no remaining NewAmsterdam Pharma position as of Q1 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 114,707 NewAmsterdam Pharma shares in Q1 2025, an estimated $2.95M.
  • Alyeska Investment Group first reported a position in NewAmsterdam Pharma in Q4 2022 and held it in 7 quarters.
  • Alyeska Investment Group's NewAmsterdam Pharma position peaked at $5.12M in Q3 2024.
  • 126 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2025.

Based on Alyeska Investment Group's 13F filing for Q1 2025, filed 15 May 2025.